**Chapter 12**

*Advances in Precision Medicine Oncology*

Dietary Nutraceuticals. Asian Pac J Cancer Prev. 16(16):6831-6839.

[121] Satonaka H, Ishida K, Takai M, Koide R, Shigemasa R, Ueyama J, Ishikawa T, Hayashi K, Goto H, Wakusawa S. (2017). (−)-Epigallocatechin-3-gallate down-regulates doxorubicin-induced overexpression of p-glycoprotein through the coordinate inhibition of pi3k/akt and mek/erk signaling

pathways. Anticancer Res

[122] Lopes-Rodrigues V, Sousa E, and Vasconcelos MH. (2016). Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives.

[123] Wang J, Ma W, and Tu P. (2015). Synergistically Improved Anti-tumor Efficacy by Co-delivery Doxorubicin and Curcumin Polymeric Micelles. Macromol Biosci. 15(9):1252-1261.

[124] Rastegar R, Akbari Javar H,

Yousefi G, Doosti M, Hossien Ghahremani M, Shariftabrizi A, Imanparast F, Gholibeglu E, and Gholami M. (2018). Evaluation of a novel biocompatible magnetic nanomedicine based on betacyclodextrin, loaded doxorubicin-

curcumin for overcoming

Pharm Biopharm. 93:27-36.

46(sup2):207-216.

chemoresistance in breast cancer. Artif Cells Nanomed Biotechnol.

[125] Zhao X, Chen Q, Li Y, Tang H, Liu W, and Yang X. (2015). Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced

hepatocellular carcinoma in mice. Eur J

Khoobi M, Dehghan Kelishadi P, Hossein

37(11):6071-6077.

Pharmaceuticals 9: 71.

[120] Zhang S, and Morris ME. (2003). Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 304(3):1258-1267. [126] Zhang J, Du Z, Pan S, Shi M, Li J, Yang C, Hu H, Qiao M, Chen D, and Zhao X. (2018). Overcoming multidrug resistance by codelivery of mdr1 targeting sirna and doxorubicin using epha10-mediated ph-sensitive lipoplexes: in vitro and in vivo

evaluation. ACS Appl Mater Interfaces.

Kreutzer B, Gouveia LF, Silva-Lima B, Brito AM, and Videira M. (2017). Evading

10(25):21590-21600.

110:76-84.

[127] Cavaco MC, Pereira C,

P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles. Eur J Pharm Biopharm

[128] Yu J, Hu F, Zhu Q, Li X, Ren H, Fan S, Qian B, Zhai B, Yang D. (2020). PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers.

Nanoscale Res Lett 15(1):59.

24(4):8.3-810.

[129] Chavanpatil MD, Khdair A, and Panyam J. (2007). Surfactantpolymer Nanoparticles: A Novel Platform for Sustained and Enhanced Cellular Delivery of Water-soluble Molecules. Pharmaceutical Research

[130] Susa M, Iyer AK, Ryu K, Choy E, Hornicek FJ, Mankin H, Milane L, Amiji MM, and Duan Z. (2010). Inhibition of ABCB1 (MDR1)

Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma. PLoS One. 5(5): e10764.

[131] Pramanik D, Campbell NR, Das S, Gupta S, Chenna V, Bisht S, Sysa-Shah P, Bedja D, Karikari C,

Steenbergen C, Gabrielson KL, Maitra A, and Maitra A. (2012). A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy.

Expression by an siRNA

Oncotarget 3(6):640-650.

**210**
